DK671187A - Anvendelse af 5-aryl-3h-1,2,4-triazol-3-oner ved behandling af neurodegenerative sygdomme - Google Patents

Anvendelse af 5-aryl-3h-1,2,4-triazol-3-oner ved behandling af neurodegenerative sygdomme

Info

Publication number
DK671187A
DK671187A DK671187A DK671187A DK671187A DK 671187 A DK671187 A DK 671187A DK 671187 A DK671187 A DK 671187A DK 671187 A DK671187 A DK 671187A DK 671187 A DK671187 A DK 671187A
Authority
DK
Denmark
Prior art keywords
triazol
aryl
treatment
oner
neurodegenerative diseases
Prior art date
Application number
DK671187A
Other languages
English (en)
Other versions
DK671187D0 (da
DK172668B1 (da
Inventor
Francis P Miller
Stephen Sorenson
John M Kane
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Publication of DK671187D0 publication Critical patent/DK671187D0/da
Publication of DK671187A publication Critical patent/DK671187A/da
Application granted granted Critical
Publication of DK172668B1 publication Critical patent/DK172668B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK198706711A 1986-12-19 1987-12-18 5-Aryl-3H-1,2,4-triazol-3-oner, deres anvendelse til fremstilling af lægemidler til behandling af neurodegenerative sygdomm DK172668B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US94463486A 1986-12-19 1986-12-19
US94463486 1986-12-19
US10700187A 1987-10-16 1987-10-16
US10700187 1987-10-16

Publications (3)

Publication Number Publication Date
DK671187D0 DK671187D0 (da) 1987-12-18
DK671187A true DK671187A (da) 1988-06-20
DK172668B1 DK172668B1 (da) 1999-05-10

Family

ID=26804275

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198706711A DK172668B1 (da) 1986-12-19 1987-12-18 5-Aryl-3H-1,2,4-triazol-3-oner, deres anvendelse til fremstilling af lægemidler til behandling af neurodegenerative sygdomm

Country Status (9)

Country Link
EP (1) EP0273309B1 (da)
JP (1) JP2593084B2 (da)
KR (1) KR880007495A (da)
AT (1) ATE116851T1 (da)
DE (1) DE3750979T2 (da)
DK (1) DK172668B1 (da)
ES (1) ES2069528T3 (da)
GR (1) GR3015685T3 (da)
IE (1) IE65857B1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966909A (en) * 1989-12-20 1990-10-30 Merrell Dow Pharmaceuticals 4-benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-ones and their use as anticonvulsants
AU644500B2 (en) * 1990-12-20 1993-12-09 Merrell Dow Pharmaceuticals Inc. 3-aryl-5-alkylthio-4h-1,2,4-triazoles for treatment of hyperreflexia due to spinal trauma
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
DE19816882A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Triazolone mit neuroprotektiver Wirkung
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
ES2391461T3 (es) 2004-07-27 2012-11-27 F. Hoffmann-La Roche Ag Compuestos de benciltriazolona utilizados como inhibidores no nucleósidos de transcriptasa inversa
US8293778B2 (en) 2004-07-27 2012-10-23 Roche Palo Alto Llc Heterocyclic antiviral compounds
MX2009009920A (es) 2007-03-29 2009-10-19 Hoffmann La Roche Inhibidores no nucleosidos de transcriptasa inversa.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1126882B (de) * 1960-05-03 1962-04-05 Boehringer Sohn Ingelheim Verfahren zur Herstellung von 1,2,4-Triazolonen-(5)
BE621842A (da) * 1962-08-27
DE1545646B1 (de) * 1965-12-15 1969-09-18 Boehringer Sohn Ingelheim 1,3-Dimethyl-4-(2',4'-dichlorphenyl)-1,2,4-triazolon-(5) und Verfahren zu dessen Herstellung
DD153953A3 (de) * 1980-04-01 1982-02-17 Gottfried Schuster Mittel zur chemotherapie von virosen der kulturpflanzen
DD160447A1 (de) * 1981-03-26 1983-08-03 Johannes Dost Herbizide mittel, die 1,2,4-triazolinone-(5) enthalten
AR243171A1 (es) * 1985-10-29 1993-07-30 Merrell Pharma Inc Procedimiento para preparar 5-aril-2,4-dialquil-3h-1,2,4-triazol-3-tionas.

Also Published As

Publication number Publication date
KR880007495A (ko) 1988-08-27
ATE116851T1 (de) 1995-01-15
EP0273309B1 (en) 1995-01-11
IE65857B1 (en) 1995-11-29
JP2593084B2 (ja) 1997-03-19
EP0273309A2 (en) 1988-07-06
ES2069528T3 (es) 1995-05-16
JPS63170312A (ja) 1988-07-14
IE873459L (en) 1989-04-16
DK671187D0 (da) 1987-12-18
EP0273309A3 (en) 1991-01-09
DE3750979T2 (de) 1995-05-24
DK172668B1 (da) 1999-05-10
GR3015685T3 (en) 1995-07-31
DE3750979D1 (de) 1995-02-23

Similar Documents

Publication Publication Date Title
ATE133564T1 (de) Flupirtin in kombination mit antiparkinsonika zur bekämpfung von muskelverspannungen
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
MX9101869A (es) Ciclosporinas, composicion farmaceutica que las contiene y procedimiento para la produccion de las mismas
DK0446570T3 (da) Gabapentin og dets derivater til behandling af neurodegenerative sygdomme
ATE194593T1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
DK671187D0 (da) Anvendelse af 5-aryl-3h-1,2,4-triazol-3-oner ved behandling af neurodegenerative sygdomme
ATE131056T1 (de) Verwendung von 2,3,4,5-tetrahydro-1h-3- benzazepinen bei der behandlung von neurologischen störungen.
FI873428A7 (fi) Silmälääketieteelliset koostumukset hermodegeneraatioiden hoitoon.
ATE113591T1 (de) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva.
DK671087D0 (da) Anvendelse af 5-aryl-3h-1,2,4-triazol-3-oner som antikonvulsiva
FR2449676A1 (fr) Diamines aromatiques, leur procede de preparation et leur application au durcissement des polyurethanes
DK532087D0 (da) Farmaceutiske praeparater til behandling af hjernelidelser paa funktional og organisk basis
EP0667157A4 (en) AGENT FOR TREATING CYCLING COMPLAINTS.
IT8720436A0 (it) Processo per la preparazione del 2,4-diammino-6-(1-piperidinil)-piri mi-din-n-ossido.
DE59104649D1 (de) Verfahren zur Herstellung von N,N,N',N'-Tetraglycidyl-3,3'-dialkyl-4,4'-diaminodiphenylmethanen.
GR75239B (da)
FI873727A7 (fi) Terebraaliseen iskemiaaseen liittyvien häiriöiden hoitoon tarkoitettu terapeuttinen aine.
ES2066897T3 (es) 5,11-dihidro-6h-pirido(2,3-b)(1,4)benzodiazepin-6-onas y -tionas y su uso en la prevencion o el tratamiento del sida.
DZ1831A1 (fr) Isopropyl 2-méthoxyéthyl 4-(2-chloro-3-cyano-phényl)-1,4-dihydro 2,6-diméthyl-pyridine 3,5-dicarboxylate.
DK0412941T3 (da) Phospholipider til behandling af dissemineret sklerose
DK0593285T3 (da) Mellemprodukter og fremgangsmåder dertil til fremstilling af 5,6-dihydropyrrolo-(2,3-d)pyrimidiner
DE69626260D1 (de) Zusammensetzungen zur Vorbeugung und Behandlung von urogenitalen Störungen, die Wismut enthalten
ES556171A0 (es) Perfeccionamientos introducidos en la patente de invencion n 531.563
FR2700695B1 (fr) Composition thérapeutique nouvelle remédiant aux désordres survenant dans la sphère ORL.
ATE91886T1 (de) Praeparat zur behandlung von erektionsstoerungen.

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed